Sino Biopharmaceutical (Sino Biopharmaceutical) COGS-to-Revenue : 0.16 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical COGS-to-Revenue?

Sino Biopharmaceutical's Cost of Goods Sold for the six months ended in Dec. 2023 was $243 Mil. Its Revenue for the six months ended in Dec. 2023 was $1,530 Mil.

Sino Biopharmaceutical's COGS to Revenue for the six months ended in Dec. 2023 was 0.16.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Sino Biopharmaceutical's Gross Margin % for the six months ended in Dec. 2023 was 84.13%.

Sino Biopharmaceutical COGS-to-Revenue Historical Data

The historical data trend for Sino Biopharmaceutical's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical COGS-to-Revenue Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.20

0.22

0.20

0.17

0.19

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.21	0.19	0.14	0.21	0.16

Sino Biopharmaceutical COGS-to-Revenue Calculation

Sino Biopharmaceutical's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	698.843	/	3669.282
	=	0.19

Sino Biopharmaceutical's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	242.762	/	1529.701
	=	0.16

Sino Biopharmaceutical (OTCPK:SBHMY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Sino Biopharmaceutical's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	242.762 / 1529.701
	=	84.13 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Sino Biopharmaceutical COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.